Clinical Data Novo says oral semaglutide works in diabetic kids PharmaphorumNovo Nordisk will file oral formulations of its GLP-1 agonist semaglutide for children and adolescents with type 2 diabetes later this year.Clinical DataMetabolic & GLP-1Read full story pharminent April 23, 2026 (Last updated: April 23, 2026) Pharmaphorum Novo Nordisk will file oral formulations of its GLP-1 agonist semaglutide for children and adolescents with type 2 diabetes later this year. Clinical DataMetabolic & GLP-1Read full story Post navigation Previous: Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO changeNext: BBOT shakes up leadership as RAS competitors get more visibility Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
